Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.
A TOTALLY IMPLANTED PERIPHERAL VENOUS ACCESS DEVICE: NEW OPTIONS FOR VASCULAR ACCESS (MEETING ABSTRACT)
Proc Annu Meet Am Soc Clin Oncol; 10:A1209 1991. Unique Identifier : AIDSLINE ICDB/91672546 Schuman E; Galen W; Winters V; Good Samaritan Hosp. and Medical Center, Portland, OR
Abstract:
From September 1988 through August 1990, 63 devices were implanted in 61 patients (pts) for chronic venous access. Although most of the pts were receiving cancer-related therapies, 29% of the devices were placed for treatment of AIDS. The catheters were in place an av of 213 days with a total experience of almost 15,000 catheter days. Twelve pts have died with functioning peripheral ports in place. Six pts completed therapy and desired that their ports be removed. Thirty-seven pts are alive with functioning peripheral ports, and only 6 pts needed to have their ports removed due to a complication. The majority of the ports were placed in the out-patient Cancer Center under local anesthetic, thus avoiding hospital admission. The ports were usually placed in the nondominant forearm into the basilic vein, cephalic vein, or vena comitantes. Early in the experience there were two pts in whom the port could not be placed due to inadequate vessels. Since a more aggressive approach was undertaken, 100% of the attempts have been successful. Complications have occurred in 17 pts, the majority of problems involving difficulty in aspirating blood. This was simply treated with a thrombolytic agent. Five pts developed thrombophlebitis but none required catheter removal. There were two episodes of catheter sepsis and two needle site infections, all treated successfully. There were three port pocket infections which required removal of the port. Two of these were in AIDS pts. This evaluation shows that totally implanted peripheral venous access can be an excellent option for long-term venous therapy.
Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY Antineoplastic Agents/ADMINISTRATION & DOSAGE Antiviral Agents/ADMINISTRATION & DOSAGE Catheterization, Peripheral/*INSTRUMENTATION *Catheters, Indwelling Fibrinolytic Agents/THERAPEUTIC USE Human Neoplasms/*DRUG THERAPY Thrombosis/PREVENTION & CONTROL ABSTRACT 911030
M91A1121
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.
